ZYBRESTAT(TM) (CA4P) Improves Overall Survival in a Phase 2/3 Trial (FACT Study) of Patients With Anaplastic Thyroid Cancer (

Median Overall Survival of Patients Receiving ZYBRESTAT Plus Chemotherapy was 5.1 Months, Compared With 4.1 Months for Patients Receiving Chemotherapy Alone

Patients Alive at One-Year More Than Doubled With ZYBRESTAT Plus Chemotherapy Compared With Chemotherapy Alone (23% Vs. 9%)

Almost Half of Patients Treated With ZYBRESTAT Plus Chemotherapy (48%) Were Alive at Six Months, Compared With 37% [...] http://bit.ly/chOnMX